Sunesis

Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing and commercializing novel oncology therapeutics. Founded in 1998 and incorporated in Delaware, the company applies its expertise in small-molecule drug discovery to advance treatments for hematologic and solid tumor malignancies. Its lead program, voreloxin, is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. Sunesis has built deep capabilities across all phases of oncology drug development, from preclinical research through Phase III clinical trials, partnering with leading academic and medical research institutions.